GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (STU:6LP) » Definitions » Effective Interest Rate on Debt %

Bolt Biotherapeutics (STU:6LP) Effective Interest Rate on Debt % : 0.00% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Bolt Biotherapeutics's annualized positive value of Interest Expense for the quarter that ended in Sep. 2024 was €0.00 Mil. Bolt Biotherapeutics's average total debt for the quarter that ended in Sep. 2024 was €16.96 Mil. Therefore, Bolt Biotherapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2024 was 0.00%.


Bolt Biotherapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Bolt Biotherapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bolt Biotherapeutics Effective Interest Rate on Debt % Chart

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial - - - - -

Bolt Biotherapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bolt Biotherapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Bolt Biotherapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bolt Biotherapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Bolt Biotherapeutics's Effective Interest Rate on Debt % falls into.



Bolt Biotherapeutics Effective Interest Rate on Debt % Calculation

Bolt Biotherapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  0/( (21.345+18.541)/ 2 )
=-1  *  0/19.943
=0.00 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=19.088 + 2.257
=21.345

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=15.99 + 2.551
=18.541

Bolt Biotherapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Sep. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Jun. 2024 )+Total Debt  (Q: Sep. 2024 ))/ count )
=-1  *  0/( (17.549+16.377)/ 2 )
=-1  *  0/16.963
=0.00 %

where

Total Debt  (Q: Jun. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=14.767 + 2.782
=17.549

Total Debt  (Q: Sep. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=13.833 + 2.544
=16.377

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Sep. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Bolt Biotherapeutics  (STU:6LP) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Bolt Biotherapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bolt Biotherapeutics Business Description

Industry
Traded in Other Exchanges
Address
900 Chesapeake Drive, Redwood, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Bolt Biotherapeutics Headlines

No Headlines